Research documents a measurable delay between when families first notice cognitive changes and when they act. Addressing that interval may matter as much as improving diagnostic pathways.
The Hesitation Gap
Families notice cognitive changes before the healthcare system does. Two decades of help-seeking research document delays of 1.5 to 2.5 years between when subtle changes are first observed at home and when any formal guidance is sought. A 2025 systematic review published in the International Journal of Geriatric Psychiatry, drawing on 13 studies and more than 30,000 participants, found the average time from symptom onset to confirmed dementia diagnosis is 3.5 years.
This interval, the period between first noticing and first acting, is not primarily a function of healthcare access. People with insurance, established primary care relationships, and available clinical pathways wait. The delay is behavioral. And the dominant behavioral mechanism is information avoidance.
Why Avoidance Drives the Delay
A 2025 study in the Journal of Alzheimer's Disease found that fear of a dementia diagnosis is directly associated with lower willingness to seek screening, even among people who already have cognitive concerns. A systematic review of help-seeking in older adults without dementia finds the same pattern: the more worried someone is, the less likely they are to ask. The awareness campaign designed to motivate action can trigger the exact withdrawal it intends to prevent.
A 2019 survey of 1,234 U.S. adults conducted by Versta Research for the Alzheimer's Association found that three in four Americans report that initiating a conversation about cognitive concerns with a family member would be challenging, even as nine in ten say they would want to be told if something were changing. That gap is not a communication failure. It is a behavioral one. People understand that the conversation matters. They delay it anyway.
The World Alzheimer Report 2019, drawing on surveys across 155 countries, found that 35 percent of caregivers globally conceal a family member's cognitive changes from others due to fear of stigma. Sixty-two percent of healthcare providers worldwide hold the belief that cognitive decline is a normal and inevitable part of aging, a belief that limits clinical inquiry even when patients present with concerns.
The Equity Dimension
The hesitation gap is not distributed equally. Structural inequity compounds the delay at every stage of the care pathway, beginning with the tools used to evaluate cognition.
A 2024 study published in the Journal of the American Geriatrics Society examined 231 older adults attending primary care in the Bronx, New York, a population that was 43 percent Hispanic and 39 percent Black or African American. Using the standard published Montreal Cognitive Assessment (MoCA) cut-point, the study found a false-positive rate of 79 percent for mild cognitive impairment. The tool, applied as designed, systematically misclassified patients because it was not developed for or validated against the populations it was being used to evaluate.
Separate research published in JAMA Network Open looked at 204 adults 65 and older at five federally qualified health centers in Indianapolis, none of whom had a prior cognitive diagnosis. 62.3 percent met diagnostic criteria for mild cognitive impairment, and 12.3 percent had undiagnosed dementia. After adjusting for age, sex, and years of education, African American individuals had 2.73 times the odds of undiagnosed cognitive impairment compared to White individuals.
These findings describe a structural design problem, not a patient failure. When standard screening instruments produce high false-positive rates in diverse populations, and when the communities most dependent on federally qualified health centers face the highest rates of undiagnosed impairment, the existing infrastructure is not serving the populations it most urgently needs to reach.
What's Missing
The public health response to cognitive health has focused on three things: campaigns to route people into clinical evaluation, academic research on why people delay, and post-diagnosis support networks.
What's missing is a sustained presence in the interval before any of those pathways begins, one that doesn't require entering a disease frame. The Alzheimer's Association and Ad Council's 2019 "Our Stories" campaign came closest to occupying this space, gathering family narratives around the experience of noticing early changes and initiating the first conversation. It ran as a time-limited campaign, was anchored to an Alzheimer's diagnosis frame, and did not produce an ongoing platform, a behavioral research program, or a product designed specifically for the pre-diagnostic interval.
Eli Lilly's 2025 "Brain Health Matters" campaign, the most recent and best-resourced public effort, encourages early clinical conversation but is pharmaceutical-sponsored and oriented toward diagnostic action. No major ongoing platform exists whose primary purpose is to meet families in the hesitation gap, before a diagnosis, before the conversation, before anyone has named what they're seeing.
What We're Building at Mentage
At Mentage, we're building specifically for this interval. MEVA is a web- and tablet-accessible cognitive wellness platform built on Montessori design principles: hands-on real-world tasks, self-directed pace, error-neutral engagement, and consent-based sharing of results. MEVA is not a diagnostic instrument. It operates within the FDA General Wellness Policy for Low-Risk Devices and has not undergone independent clinical trials.
The MEVA Wellness Validation Protocol Study (MEVA-WVP-001) is in active contracting with Piedmont HealthCare, PA (Principal Investigator: Dr. Dwight Bellingham, MD). IRB submission through BRANY is targeted for April 2026, with planned recruitment beginning July 2026. The study will enroll 100 participants, including 40 retest pairs, to evaluate the test-retest reliability of the Global Cognitive Index across a diverse adult population aged 55 to 75. The study has not yet received IRB approval. No outcomes are available.
Mentage Element's Active Recall & Connection ARC product is a two-person conversation and cognitive engagement ritual kit for older adults and adult children. It is designed to lower the barrier to the first wellness conversation before any clinical concern has been named. Both products are built on the Montessori principle that the environment should reduce friction for the learner, not raise it. Neither is a diagnostic tool. Both are designed specifically for the hesitation gap: the space before a family is ready to call what they are observing a clinical matter.
Regulatory & Informational Disclaimer
This brief is provided for informational and educational purposes only and does not constitute medical advice, clinical guidance, or diagnostic recommendation. Mentage LLC operates within the framework of the FDA General Wellness Policy for Low-Risk Devices. MEVA is a general wellness tool. It is not a medical device and has not been cleared or approved by the FDA for any clinical indication. MEVA has not undergone independent clinical trials. The MEVA-WVP-001 study is in active contracting and has not yet received IRB approval. No outcomes from that study are available or should be inferred from this document. Study protocol is subject to IRB review and modification.
References
- Knopman DS, Donohue JA, Gutterman EM. Patterns of care in the early stages of Alzheimer's disease: impediments to timely diagnosis. J Am Geriatr Soc. 2000;48(3):300-304.
- Chrisp TAC, Thomas BD, Goddard WA, Owens A. Dementia timeline: journeys, delays and decisions on the pathway to an early diagnosis. Dementia. 2011;10(4).
- Kusoro O, Roche M, Del-Pino-Casado R, Leung P, Orgeta V. Time to diagnosis in dementia: A systematic review with meta-analysis. Int J Geriatr Psychiatry. 2025;e70129.
- Orom H, Allard NC. Information avoidance is associated with lower willingness to be screened for dementia. J Alzheimers Dis. 2025.
- Alzheimer's Disease International. World Alzheimer Report 2019: Attitudes to Dementia. London: ADI; 2019.
- Alzheimer's Association. New Alzheimer's Campaign Encourages Families to Discuss Cognitive Problems Sooner, Enabling Early Diagnosis. Press Release. June 3, 2019.
- Hill NL, Bratlee-Whitaker E, Sillner A, Brautigam L, Mogle J. Help-seeking for cognitive problems in older adults without dementia: A systematic review. Int J Nurs Stud Adv. 2021;3:100050.
- Stimmel MB, Orkaby AR, Ayers E, Verghese J, Nsubayi CK, Weiss EF. Is the Montreal cognitive assessment culturally valid in a diverse geriatric primary care setting? Lessons from the Bronx. J Am Geriatr Soc. 2024;72(3):850-857.
- Kulshreshtha A, Parker ES, Fowler NR, et al. Prevalence of unrecognized cognitive impairment in federally qualified health centers. JAMA Netw Open. 2024;7(10):e2440411.
- Alzheimer's Association / Ad Council. Our Stories Campaign. 2019. ourstories.alz.org
- Lilly. Brain Health Matters. 2025. brainhealthmatters.lilly.com